Sign inJoin waitlistJoin the waitlist

JA

Jacob Aelion

Clinical Professor of Medicine, UT Health Science Center, Diretor, West Tennessee Research Institute · University of Tennessee College of Medicine

Credentials: · ·

History

UT Health Science Center · University of Tennessee College of Medicine
Present
University of Tennessee College of Medicine
Present

Rheumatology
1982–1984
Internal Medicine
1979–1982
Doctor of Medicine
1975–1979

Research

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study
Annals of the Rheumatic Diseases · 2013 · 237 citations
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
Annals of the Rheumatic Diseases · 2016 · 222 citations
Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis
Journal of Clinical Investigation · 1995 · 222 citations

AK
Alan Kivitz
5 papers
HR
Hanno Richards
5 papers
Mark Genovese
5 papers
Andrew Kang
3 papers
MC
Michael Cremer
3 papers
AW
Alvin Wells
2 papers
AE
Ann Eldred
2 papers
AP
Arnold Postlethwaite
2 papers
AD
Atul Deodhar
2 papers
CC
Christine Codding
2 papers
Kun Chen
2 papers · 2 as a resident
LM
Linda Myers
2 papers

Clinical trials

Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2026–2033
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Site PI · Recruiting · Phase 3
Takeda
2026–2029
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Site PI · Recruiting · Phase 3
Takeda
2025–2028
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
Site PI · Recruiting · Phase 2
Novartis Pharmaceuticals
2024–2034